AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$5.22 +0.82%

+$0.04 today

Market cap
$198.07M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.79M

Average 0.29M

Returns on capital

AN2 Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-66.3%

avg -207.9%

ROIC

-71.6%

avg -156.6%

ROA

-56.8%

avg -163.8%

Analysis

ROA is currently the strongest return metric at -56.8% versus its period average of -163.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Eric E. Easom

Co-Founder, Chief Executive Officer, President & Chairman of the BoardUSD 943.31K58——

Cameron Trenor

Chief Medical OfficerUSD 688.2K———

Lucy O. Day

CFO, & Principal Financial OfficerUSD 633.58K66——

Josh Eizen

Chief Legal Officer, Chief Operating Officer & Corporate SecretaryUSD 630K47——

Joseph S. Zakrzewski

Co-Founder & Independent DirectorUSD 51.5K640<0.01%

Michael R. K. Alley

Co-founder & Head of Biology————

Sanjay Chanda

Chief Development Officer—600<0.01%

Vince Hernandez

Head of Research————

Sarah Williams

Vice President of Controller & Principal Accounting Officer—38——

George Harrison Talbot FACP

Co-Founder & Senior Clinical Advisor—78——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 14, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$11,601.94

Sells

21

$406,138.10

Net Transaction Value

−$394,536.16

Net selling

Most Active

Readnour Robin Shane

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

Eizen Joshua M

Direct

Sell$11.9K
Sep 9, 26

Readnour Robin Shane

Indirect

Sell$3.2K
Sep 9, 26

Readnour Robin Shane

Indirect

Sell$3.5K
Sep 8, 26

Readnour Robin Shane

Indirect

Sell$31.9K
Sep 8, 26

Readnour Robin Shane

Indirect

Sell$28.4K
Sep 3, 26

Readnour Robin Shane

Indirect

Sell$17.5K
Sep 3, 26

Readnour Robin Shane

Indirect

Sell$19.6K
Sep 1, 26

Williams Sarah Joanne

Direct

Sell$1.5K
Sep 1, 26

FitzPatrick Margaret M

Direct

Buy$11.6K
Aug 17, 26

Readnour Robin Shane

Indirect

Sell$112.4K

1–10 of 22

Summary

Insiders reported 1 buys worth $11,601.94 and 21 sells worth $406,138.10 over the last 12 months. That adds up to net selling of $394,536.16. Readnour Robin Shane was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does AN2 Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ANTX's management, answered from reported figures.

Who manages ANTX?

AN2 Therapeutics, Inc. (ANTX) lists 10 active executives. The top listed executive is Cameron Trenor, Chief Medical Officer.

Are ANTX insiders buying or selling?

Recent insider activity shows net selling of $16.32M.